• Home
  •  
    Regions
    • Europe
    • UK & Ireland
    • DACH
    • Nordic
    • France
    • Southern Europe
    • Benelux
    • CEE
    • Asia
  •  
    Deals
    • Buyouts
    • Venture
    • Exits
    • Refinancings
    • Build-up
    • Turnaround
    • Secondaries
    • Advanced deal search
  •  
    Funds
    • Buyout
    • Venture
    • Mezzanine
    • Debt
    • Funds-of-funds
    • Secondaries
    • Fundraising pipelines
    • Advanced funds search
  •  
    GPs & LPs
    • GP profiles
    • LP profiles
    • GP news
    • LP news
    • Sponsors search
    • LPs search
  •  
    Secondaries
    • Deals
    • Funds
    • News
    • Analysis
  •  
    People
    • People moves
    • Analysis
    • In Profile
    • Q&A
    • Videos
    • Comment
  •  
    Analysis
    • In Profile
    • Fundraising
    • Q&A
    • Comment
    • Videos
    • Podcast
    • Reports
    • Data Snapshots
  •  
    Unquote Data
    • Deals search
    • Exits search
    • Funds search
    • Sponsors search
    • Advisers search
    • LPs search
    • League tables
    • Reports
  • Sign in
  • Sign in
    • You are currently accessing unquote.com via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0)203 741 1137

      Email: Georgina.Lawson@acuris.com

      • Sign in
     
      • Newsletters
      • Account details
      • Contact support
      • Sign out
     
  • Follow us
    • Twitter
    • LinkedIn
  • Free Trial
  • Subscribe
Unquote
Unquote
  • Home
  • Regions
  • Deals
  • Funds
  • GPs & LPs
  • Secondaries
  • People
  • Analysis
  • Unquote Data
      • Deals search
      • Exits search
      • Funds search
      • Sponsors search
      • Advisers search
      • LPs search
      • League tables
      • Reports
  • You are currently accessing unquote.com via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0)203 741 1137

    Email: Georgina.Lawson@acuris.com

    • Sign in
 
    • Newsletters
    • Account details
    • Contact support
    • Sign out
 
UNQUOTE
  • Healthcare

SHS nears EUR 250m hard cap on sixth fund

  • Rachel Lewis
  • 21 July 2022
  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  

SHS Gesellschaft, a German specialist healthcare investor, has held a EUR 220m first close on its sixth fund, just EUR 30m shy of the fund’s hard cap.

SHS VI has already exceeded its EUR 200m target and has a hard cap of EUR 250m, which it hopes to reach in the coming weeks with commitments from LPs already underway, the GP's managing partner Uwe Steinbacher told Unquote.

The fund's predecessor, SHS V, closed at EUR 130m in July 2019, short of its EUR 150m target, and is near full deployment, said Steinbacher. 

The raise comes at a time of heightened interest in healthcare GPs, in what is set to be a record year for specialist fundraising. "We have done investments with other private equity funds," said Steinbacher. "We bring expertise and insight into the healthcare system for many funds who are quite agnostic."

Recent deals of joint equity tickets include its expansion investment into Norweigan digital health platform Dr.Dropin, alongside Yabeo Capital.

Investors

SHS VI already has around 60 investors with more than half of those participating in the firm's predecessor funds. They include funds-of-funds, insurance companies, pension funds, foundations, family offices, banks, healthcare groups, church investors and entrepreneurs.

Among the fund's largest investors are the European Investment Fund, Scandinavian foundation Realdania, Switzerland's Helsana HealthInvest, L-Bank Baden-Württemberg and larger family offices. SHS also said it has also made a significant investment in the vehicle.

Investments

Like its predecessor, Fund VI will aim to make around 12-15 investments across its 10+2 life span and will make both buyout and growth capital investments. It targets companies that are profitable or with a clear path to profitability, but not those that are pre-revenue.

The average ticket size will be EUR 15m up to a maximum of EUR 50m, said Steinbacher. If the investment requires far more than 20% of the fund, the GP will seek co-investment from its LPs.

The fund will invest across different healthcare subsectors, including medical devices, diagnostics, digital health, healthcare services, and life sciences. It will not, however, finance early-stage drug development companies because the time they take to come to market is often longer than the lifetime of the fund.

The fund is focused on making investments in expansion and innovation financing, succession situations and shareholder changes.

SHS invests across Europe with an emphasis on DACH, Benelux and the Nordics.

  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  
  • Topics
  • Healthcare
  • Buyout
  • GPs
  • healthcare
  • SHS Gesellschaft für Beteiligungsmanagement

More on Healthcare

Gyrus Capital acquires LRE Medical from KPS-backed AIS Global
Gyrus Capital acquires LRE Medical from KPS-backed AIS Global

Carve-out of German diagnostic equipment manufacturer comes over two years after first sale attempt

  • Healthcare
  • 26 May 2023
Forbion raises combined EUR 1.35bn for venture and growth funds
Forbion raises combined EUR 1.35bn for venture and growth funds

Ventures Fund VI closes on EUR 750m and Growth Opportunities II on EUR 600m with both upsized by over 60%

  • Healthcare
  • 19 April 2023
EQT closes LSP Dementia on EUR 260m hard cap
EQT closes LSP Dementia on EUR 260m hard cap

Series A-focused fund exceeded its EUR 100m target and extended fundraising after increased LP interest in its strategy

  • Healthcare
  • 30 March 2023
Ardian reinvests in Neopharmed alongside NB Renaissance
Ardian reinvests in Neopharmed alongside NB Renaissance

French GP will move stake from fund VI to VII; additional capital allows for European M&A

  • Healthcare
  • 10 November 2022

Latest News

Partners Group to release IMs for Civica sale in mid-September
  • Exits
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017

  • 04 September 2023
BHM Group builds on PE strategy, eyes European medtech and renewable energy acquisitions
  • Investments
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Czech Republic-headquartered family office is targeting DACH and CEE region deals

  • 01 September 2023
Redalpine expands leadership team amid CHF 1bn-plus fundraise
  • Venture
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO

  • 31 August 2023
Change Ventures aims to hold final close for EUR 20m third fund by mid-2024
  • Funds
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds

  • 31 August 2023
Back to Top
  • About Unquote
  • Advertise
  • Contacts
  • About Acuris
  • Terms of Use
  • Privacy Policy
  • Group Disclaimer
  • Twitter
  • LinkedIn

© Merger Market

© Mergermarket Limited, 10 Queen Street Place, London EC4R 1BE - Company registration number 03879547

Digital publisher of the year 2010 & 2013

Digital publisher of the year 2010 & 2013